The meningioma enhancer landscape delineates novel subgroups and drives druggable dependencies

Briana C. Prager, Harish N. Vasudevan, Deobrat Dixit, Jean A. Bernatchez, Qiulian Wu, Lisa C. Wallace, Shruti Bhargava, Derrick Lee, Bradley H. King, Andrew R. Morton, Ryan C. Gimple, Melike Pekmezci, Zhe Zhu, Jair L. Siqueira-Neto, Xiuxing Wang, Qi Xie, Clark Chen, Gene H. Barnett, Michael A. Vogelbaum, Stephen C. MackLukas Chavez, Arie Perry, David R. Raleigh, Jeremy N. Rich

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Meningiomas are the most common primary intracranial tumor with current classification offering limited therapeutic guidance. Here, we interrogated meningioma enhancer landscapes from 33 tumors to stratify patients based upon prognosis and identify novel meningioma-specific dependencies. Enhancers robustly stratified meningiomas into three biologically distinct groups (adipogenesis/cholesterol, mesodermal, and neural crest) distinguished by distinct hormonal lineage transcriptional regulators. Meningioma landscapes clustered with intrinsic brain tumors and hormonally responsive systemic cancers with meningioma subgroups, reflecting progesterone or androgen hormonal signaling. Enhancer classification identified a subset of tumors with poor progno-sis, irrespective of histologic grading. Superenhancer signatures predicted drug dependencies with superior in vitro efficacy to treatment based upon the NF2 genomic profile. Inhibition of DUSP1, a novel and druggable meningioma target, impaired tumor growth in vivo. Collectively, epigenetic landscapes empower meningioma classification and identification of novel therapies. SIGNIFICANCE: Enhancer landscapes inform prognostic classification of aggressive meningiomas, identifying tumors at high risk of recurrence, and reveal previously unknown therapeutic targets. Drug-gable dependencies discovered through epigenetic profiling potentially guide treatment of intractable meningiomas.

Original languageEnglish (US)
Pages (from-to)1722-1741
Number of pages20
JournalCancer discovery
Issue number11
StatePublished - Nov 2020

Bibliographical note

Publisher Copyright:
© 2020 American Association for Cancer Research.


Dive into the research topics of 'The meningioma enhancer landscape delineates novel subgroups and drives druggable dependencies'. Together they form a unique fingerprint.

Cite this